The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway

Kidney International

Volumn 84, Issue 6, 2013, Pages 1129-1144

  Li, Rong ^a,b,c   Chung, Arthur C K ^a,b   Dong, Yuan ^a   Yang, Weiqin ^b   Zhong, Xiang ^a,b   Lan, Hui Y ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c First Hospital of Yunnan Province   (China)

Author keywords

microRNA therapy; miR 433; renal fibrosis; TGF signaling

Indexed keywords

ANTIENZYME INHIBITOR AZIN1; MICRORNA; MICRORNA 433; PEPTIDES AND PROTEINS; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; MICROBUBBLE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; POSITIVE FEEDBACK; PREVENTION STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; ULTRASOUND;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; BINDING SITES; CARRIER PROTEINS; CELL LINE; DISEASE MODELS, ANIMAL; DOXORUBICIN; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; PROMOTER REGIONS, GENETIC; RATS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; URETERAL OBSTRUCTION;

EID: 84888638018     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.272     Document Type: Article

References (71)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
2. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279-284.
3. Muller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000; 15(Suppl 6): 76-77.
4. Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 1998; 24: 190-196.
5. Schnaper HW, Hayashida T, Hubchak SC et al. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284: F243-F252.
6. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
7. Deelman L, Sharma K. Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens 2009; 18: 85-90.
8. Yu L, Border WA, Anderson I et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66: 1774-1784.
9. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012; 32: 236-243.
10. Meng XM, Huang XR, Xiao J et al. Diverse roles of TGF-beta receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol 2012; 227: 175-188.
11. Meng XM, Huang XR, Xiao J et al. Disruption of Smad4 impairs TGF-beta/
12. Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 2012; 81: 266-279.
13. Yaswen L, Kulkarni AB, Fredrickson T et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996; 87: 1439-1445.
14. Lan HY, Chung AC. Transforming growth factor-beta and Smads. Contrib Nephrol 2011; 170: 75-82.
15. Zhong X, Chung AC, Chen HY et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22: 1668-1681.
16. Chung AC, Huang XR, Meng X et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325.
17. Qin W, Chung AC, Huang XR et al. TGF-{beta}/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011; 22: 1462-1474.
18. Chung AC, Dong Y, Yang W et al. Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol Ther 2013; 21: 388-398.
19. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011; 7: 286-294.
20. Zhong X, Chung AC, Chen HY et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56: 663-674.
21. Zavadil J, Narasimhan M, Blumenberg M et al. Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 2007; 185: 157-161.
22. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 2011; 7: 1056-1067.
23. Kriegel AJ, Fang Y, Liu Y et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor b1: A novel role of miR-382. Nucleic Acids Res 2010; 38: 8338-8347.
24. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007; 104: 3432-3437.
25. Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008; 22: 4126-4135.
26. Park SM, Gaur AB, Lengyel E et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
27. Kato M, Putta S, Wang M et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881-889.
28. Krupa A, Jenkins R, Luo DD et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438-447.
29. Ng YY, Hou CC, Wang W et al. Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl 2005; S83-S91.
30. Lan HY, Mu W, Tomita N et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535-1548.
31. Hou CC, Wang W, Huang XR et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005; 166: 761-771.
32. Ka SM, Huang XR, Lan HY et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007; 18: 1777-1788.
33. Li JH, Zhu HJ, Huang XR et al. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464-1472.
34. Zhou L, Fu P, Huang XR et al. Mechanism of chronic aristolochic acid nephropathy: Role of Smad3. Am J Physiol Renal Physiol 2010; 298: F1006-F1017.
35. Yang F, Chung AC, Huang XR et al. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: The role of Smad3. Hypertension 2009; 54: 877-884.
36. Sato M, Muragaki Y, Saika S et al. Targeted disruption of TGF-beta1/
37. Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494.
38. Meng XM, Huang XR, Chung AC et al. Smad2 protects against TGF-{beta}/ Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010; 21: 1477-1487.
39. Loots GG, Ovcharenko I. rVISTA 2.0: Evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 2004; 32: W217-W221.
40. Grimson A, Farh KK, Johnston WK et al. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell 2007; 27: 91-105.
41. Wang X. miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA 2008; 14: 1012-1017.
42. Betel D, Wilson M, Gabow A et al. The microRNA.org resource: Targets and expression. Nucleic Acids Res 2008; 36: D149-D153.
43. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006; 3: 881-886.
44. Paris AJ, Snapir Z, Christopherson CD et al. A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology 2011; 54: 2198-2207.
45. Kahana C. Regulation of cellular polyamine levels and cellular proliferation by antizyme and antizyme inhibitor. Essays Biochem 2009; 46: 47-61.
46. Liu L, Santora R, Rao JN et al. Activation of TGF-beta-Smad signaling pathway following polyamine depletion in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2003; 285: G1056-G1067.
47. Rao JN, Li L, Bass BL et al. Expression of the TGF-beta receptor gene and sensitivity to growth inhibition following polyamine depletion. Am J Physiol Cell Physiol 2000; 279: C1034-C1044.
48. Patel AR, Li J, Bass BL et al. Expression of the transforming growth factorbeta gene during growth inhibition following polyamine depletion. Am J Physiol 1998; 275: C590-C598.
49. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998; 24: 111-119.
50. Zhang R, Zhang YY, Huang XR et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010; 55: 953-960.
51. Chung AC, Lan HY. Chemokines in renal injury. J Am Soc Nephrol 2011; 22: 802-809.
52. Li ZI, Chung AC, Zhou L et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Lab Invest 2011; 91: 837-851.
53. Liu F, Chen HY, Huang XR et al. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia 2011; 54: 2713-2723.
54. Landau G, Bercovich Z, Park MH et al. The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation. J Biol Chem 2010; 285: 12474-12481.
55. Meng XM, Chung AC, Lan HY. Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 2013; 124: 243-254.
56. Chen H, Huang XR, Wang W et al. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes 2010; 60: 590-601.
57. Luo H, Zhang H, Zhang Z et al. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 2009; 28: 82.
58. Jung MH, Kim SC, Jeon GA et al. Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 2000; 69: 281-286.
59. Alessandra C, Andrea B, Floriana M et al. Polyamines modulate epithelialto-mesenchymal transition. Amino Acids 2012; 42: 783-789.
60. Chung AC, Huang XR, Zhou L et al. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009; 24: 1443-1454.
61. Chung AC, Zhang H, Kong YZ et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010; 21: 249-260.
62. Huang XR, Chung AC, Zhou L et al. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 2008; 19: 233-242.
63. Yang X, Letterio JJ, Lechleider RJ et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. Embo J 1999; 18: 1280-1291.
64. Ju W, Ogawa A, Heyer J et al. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol Cell Biol 2006; 26: 654-667.
65. Li R, Rosendahl A, Brodin G et al. Deletion of exon I of SMAD7 in mice results in altered B cell responses. J Immunol 2006; 176: 6777-6784.
66. Yang F, Huang XR, Chung AC et al. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol 2010; 221: 390-401.
67. Koka V, Huang XR, Chung AC et al. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008; 172: 1174-1183.
68. Moon JA, Kim HT, Cho IS et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70: 1234-1243.
69. Huang XR, Chung AC, Wang XJ et al. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 2008; 295: F118-F127.
70. Lan HY, Hutchinson P, Tesch GH et al. A novel method of microwave treatment for detection of cytoplasmic and nuclear antigens by flow cytometry. J Immunol Methods 1996; 190: 1-10.
71. Bercovich Z, Snapir Z, Keren-Paz A et al. Antizyme affects cell proliferation and viability solely through regulating cellular polyamines. J Biol Chem 2011; 286: 33778-33783.